PF 6372865

Drug Profile

PF 6372865

Alternative Names: PF-06372865; PF-6372865

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Back pain; Epilepsy
  • Discontinued Generalised anxiety disorder

Most Recent Events

  • 07 Feb 2017 Pfizer completes a phase II trial in Epilepsy in USA (PO) (NCT02564029)
  • 16 Dec 2015 Phase-II clinical trials in Epilepsy in USA (PO) (NCT02564029)
  • 28 Oct 2015 Discontinued - Phase-II for Generalised anxiety disorder (Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top